Empagliflozin and metformin synergy in proximal tubular epithelial cells: does the combination alleviates hyperglycaemia-induced metabolic stress?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00135246" target="_blank" >RIV/00216224:14110/23:00135246 - isvavai.cz</a>

Result on the web

<a href="https://www.easd.org/media-centre/home.html?urlTarget=_blank#!resources/empagliflozin-and-metformin-synergy-in-proximal-tubular-epithelial-cells-does-the-combination-alleviates-hyperglycaemia-induced-metabolic-stress-e31dfab1-a0cb-424f-b0ea-cbebbc11adc6" target="_blank" >https://www.easd.org/media-centre/home.html?urlTarget=_blank#!resources/empagliflozin-and-metformin-synergy-in-proximal-tubular-epithelial-cells-does-the-combination-alleviates-hyperglycaemia-induced-metabolic-stress-e31dfab1-a0cb-424f-b0ea-cbebbc11adc6</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Empagliflozin and metformin synergy in proximal tubular epithelial cells: does the combination alleviates hyperglycaemia-induced metabolic stress?

Original language description

Metformin remains the drug of first choice in type 2 diabetes mellitus (T2DM) worldwide since its beneficial metabolic effects are known for a long time.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů